CliffBio
small molecule

TOVIAZ

FESOTERODINE FUMARATE

Loss of exclusivityDecember 2027latest FDA-listed patent expiry
CompanyPfizer →View the full company profile on CliffBio

Drug detail

Brand nameTOVIAZ
Active ingredientFESOTERODINE FUMARATE
Strength8MG
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2008
Marketing statusRX

Listed patents

PatentExpiresType
7807715*PEDDecember 2027—
8088398*PEDDecember 2027—
8501723*PEDDecember 2027—
8088398June 2027product
7807715June 2027product
8501723June 2027product

More from Pfizer

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TOVIAZ patent cliff — loss of exclusivity December 2027 | CliffBio